S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel

Deutsche Bank Aktiengesellschaft Initiates Coverage on BioNTech (NASDAQ:BNTX)

Last updated on Friday, October 22, 2021 | 2021 MarketBeat

Equities research analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of BioNTech (NASDAQ:BNTX) in a report released on Friday, The Fly reports. The brokerage set a "hold" rating on the stock.

Other research analysts also recently issued research reports about the company. Berenberg Bank set a $400.00 price objective on BioNTech in a research note on Tuesday, October 5th. HC Wainwright reaffirmed a "hold" rating and issued a $330.00 price objective on shares of BioNTech in a research note on Tuesday, October 5th. UBS Group set a $300.00 price objective on BioNTech in a research note on Thursday, September 23rd. Zacks Investment Research downgraded shares of BioNTech from a "buy" rating to a "hold" rating in a research report on Wednesday, October 13th. Finally, Bryan, Garnier & Co set a $359.00 target price on shares of BioNTech in a research report on Tuesday, October 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of "Hold" and an average price target of $255.36.

Shares of NASDAQ BNTX opened at $286.36 on Friday. The company has a current ratio of 2.67, a quick ratio of 2.57 and a debt-to-equity ratio of 0.04. The company has a market cap of $69.45 billion, a price-to-earnings ratio of 14.98 and a beta of -1.59. BioNTech has a 12 month low of $75.35 and a 12 month high of $464.00. The stock has a 50-day moving average price of $321.80 and a two-hundred day moving average price of $253.24.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Sunday, August 8th. The company reported $10.77 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $8.35 by $2.42. The firm had revenue of $5.31 billion during the quarter, compared to the consensus estimate of $3.27 billion. BioNTech had a return on equity of 159.73% and a net margin of 52.48%. The business's quarterly revenue was up 12599.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. On average, sell-side analysts predict that BioNTech will post 37.71 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Fosun International Ltd purchased a new stake in BioNTech in the 2nd quarter valued at $353,904,000. Coatue Management LLC raised its position in BioNTech by 261.7% in the 2nd quarter. Coatue Management LLC now owns 1,236,317 shares of the company's stock valued at $276,787,000 after buying an additional 894,471 shares during the last quarter. BlackRock Inc. raised its position in BioNTech by 99.4% in the 2nd quarter. BlackRock Inc. now owns 1,481,390 shares of the company's stock valued at $331,654,000 after buying an additional 738,532 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in BioNTech by 31.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company's stock valued at $226,559,000 after buying an additional 500,085 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in BioNTech in the 2nd quarter valued at $73,570,000. 14.49% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: Green Investing

The Fly logo

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in BioNTech right now?

Before you consider BioNTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.

While BioNTech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.